Published Papers & Misc - OKIYAMA Naoko

41. Ichimura Y, Ikei H, Konishi R, Zeniya M, Okai T, Nomura T, Negishi K, Okiyama N. Relevance of leukemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease. Rheumatology (Oxford, England). 2022.11; 62 (6): 2267-2271. ( PubMed, DOI )

42. Wada S, Namiki T, Takano M, Miura K, Okiyama N. Kaposi-Sarkom mit HHV-8-Immunreaktivität in einer Magenläsion, aber nicht in Hautläsionen. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2022.11; 20 (11): 1511-1513. ( PubMed, DOI )

43. Mouri M, Kanamori T, Tanaka E, Hiratoko K, Okubo M, Inoue M, Morio T, Shimizu M, Nishino I, Okiyama N, Mori M. Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developing during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report. Modern rheumatology case reports. 2022.11; 20 (11): 1511-1513. ( PubMed, DOI )

44. Wada S, Namiki T, Takano M, Miura K, Okiyama N. Kaposi sarcoma with HHV-8 immunoreactivity in a gastric lesion but not in skin lesions. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2022.11; 20 (11): 1512-1514. ( PubMed, DOI )

45. Hiraiwa T, Hanami Y, Okiyama N, Konishi R, Ichimura Y, Yamamoto T.. Clinically amyopathic dermatomyositis with diffuse erosive erythema in a patient with anti-small ubiquitin-like modifier activating enzyme antibody. International Journal of Dermatology. 2022.10; 61 (10): e389-e391.

46. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Okiyama N, Kodera M, Hasegawa M, Sato S. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. The Lancet. Rheumatology. 2022.08; 4 (8): e546-e555. ( PubMed, DOI )

47. Ogawa T, Ishitsuka Y, Nakamura Y, Watanabe R, Okiyama N, Fujisawa Y, Fujimoto M, Roop DR, Nomura T. Loricrin Protects against Chemical Carcinogenesis. The Journal of investigative dermatology. 2022.07; 142 (7): 2023-2026.e1. ( PubMed, DOI )

48. Tanaka R, Ichimura Y, Kubota N, Konishi R, Nakamura Y, Mizuno S, Takahashi S, Fujimoto M, Nomura T, Okiyama N. The Role of PD-L1 on Langerhans Cells in the Regulation of Psoriasis. The Journal of investigative dermatology. 2022.07; 142 (12): 3167-3174.e9. ( PubMed, DOI )

49. Nagamori T, Ishibazawa E, Yoshida Y, Izumi K, Sato M, Ichimura Y, Okiyama N, Nishino I, Azuma H. A Continuous Increase in CXC-Motif Chemokine Ligand 10 in a Case of Anti-Nuclear Matrix Protein-2-Positive Juvenile Dermatomyositis. Journal of medical cases. 2022.06; 13 (6): 290-296. ( PubMed, DOI )

50. Kobayashi T, Nakano T, Ogata H, Sato N, Yamaide F, Yamashita Y, Chikaraishi K, Hino M, Nishino I, Ichimura Y, Okiyama N, Hamada H. A 10-year-old girl with low-grade B cell lymphoma complicated by anti-nuclear matrix protein 2 autoantibody-positive juvenile dermatomyositis. Rheumatology (Oxford, England). 2022.05; 61 (6): e143-e145. ( PubMed, DOI )

51. Okune M, Okiyama N, Fukuzono M, Sasaki K, Nomura T. Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis. The Journal of dermatology. 2022.05; 49 (5): 556-559. ( PubMed, DOI )

52. Fukuzono M, Okiyama N, Iwasaki R, Endo R, Sasaki K, Inoue S, Nomura T. Intravenous immunoglobulin-induced thrombocytopenia: a case report and review of the literature European journal of dermatology : EJD. 2022.05; 32 (3): 373-376. ( PubMed, DOI )

53. Okune Mari, Okiyama Naoko, Fukuzono Maki, Sasaki Katsuhito, Nomura Toshifumi. デュピルマブ治療後に全身性エリテマトーデスを発症したアトピー性皮膚炎の1例(Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis) The Journal of Dermatology. 2022.05; 49 (5): 556-559. ( ichushi )

54. Ichimura Yuki, Konishi Risa, Shobo Miwako, Inoue Sae, Okune Mari, Maeda Akemi, Tanaka Ryota, Kubota Noriko, Matsumoto Isao, Ishii Akiko, Tamaoka Akira, Shimbo Asami, Mori Masaaki, Morio Tomohiro, Kishi Takayuki, Miyamae Takako, Tanboon Jantima, Inoue Michio, Nishino Ichizo, Fujimoto Manabu, Nomura Toshifumi, Okiyama Naoko. Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties(和訳中) The Journal of Dermatology. 2022.04; 49 (4): 441-447. ( ichushi )

55. Ichimura Y, Konishi R, Shobo M, Inoue S, Okune M, Maeda A, Tanaka R, Kubota N, Matsumoto I, Ishii A, Tamaoka A, Shimbo A, Mori M, Morio T, Kishi T, Miyamae T, Tanboon J, Inoue M, Nishino I, Fujimoto M, Nomura T, Okiyama N. Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties. The Journal of dermatology. 2022.04; 49 (4): 441-447. ( PubMed, DOI )

56. Okiyama Naoko, Tanaka Ryota. 免疫チェックポイント阻害剤による様々な臓器における免疫関連有害事象(Immune-related adverse events in various organs caused by immune checkpoint inhibitors) Allergology International. 2022.04; 71 (2): 169-178. ( ichushi )

57. Okada Y, Izumi R, Hosaka T, Watanabe S, Shijo T, Hatchome N, Konishi R, Ichimura Y, Okiyama N, Suzuki N, Misu T, Aoki M. Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy. Rheumatology (Oxford, England). 2022.04; 61 (4): e90-e92. ( PubMed, DOI )

58. Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergology international : official journal of the Japanese Society of Allergology. 2022.04; 71 (2): 169-178. ( PubMed, DOI )

59. Kakurai Masakazu, Okiyama Naoko, Ogawa Tatsuya, Fukuzono Maki, Kubota Noriko, Fujisawa Yasuhiro, Kajita Tomohide, Ishii Akiko, Tamaoka Akira, Nomura Toshifumi. Intertwined vascular skin manifestations in a patient with Sjoegren syndrome: A case report(和訳中) Journal of Cutaneous Immunology and Allergy. 2022.02; 5 (1): 22-23. ( ichushi )

60. Hiraiwa T, Hanami Y, Okiyama N, Konishi R, Ichimura Y, Yamamoto T. Clinically amyopathic dermatomyositis with diffuse erosive erythema in a patient with anti-small ubiquitin-like modifier activating enzyme antibody. International journal of dermatology. 2022.02; 61 (10): e389-e391. ( PubMed, DOI )